Intel stock extends gains after report of possible U.S. government stake
DOYLESTOWN, Pa. - Aprea Therapeutics, Inc. (NASDAQ: NASDAQ:APRE), a biopharmaceutical company with a market capitalization of $21.2 million focused on developing treatments targeting cancer cell vulnerabilities, has announced an update to its patent portfolio. The company’s stock, currently trading at $3.90, has shown resilience with an 18.54% gain year-to-date, according to InvestingPro data. The company’s President and CEO, Oren Gilad, Ph.D., emphasized the importance of intellectual property in their strategy to advance oncology treatments and protect asset value.
Aprea’s ATR inhibitor program, which includes the lead compound ATRN-119, currently in clinical trials, is backed by a strong patent estate. This estate comprises four granted U.S. patents, one pending U.S. application, and one pending provisional application. Additionally, there are 19 granted non-U.S. patents and 16 pending non-U.S. patent applications. The granted patents are set to expire between 2035 and 2037, and pending applications could extend the exclusivity period into 2044. The company may also benefit from up to five years of additional regulatory exclusivities.
The ATRN-119 is being evaluated in the ABOYA-119 clinical trial for patients with advanced solid tumors with mutations in DNA damage response-related genes. Aprea’s intellectual property also covers its WEE1 kinase inhibitor program, which includes the lead compound APR-1051, undergoing a Phase 1 clinical trial named ACESOT-1051 for advanced/metastatic solid tumors with certain gene alterations. The WEE1 program’s patent applications, if granted, will expire in 2043, not accounting for any potential regulatory exclusivities.
Aprea’s approach to cancer therapy is designed to exploit specific cancer cell mutations while minimizing the impact on healthy cells, potentially reducing toxicity associated with conventional treatments. The company’s technology aims to address various tumor types, including ovarian, colorectal, prostate, and breast cancers.
The press release includes forward-looking statements regarding Aprea’s clinical trials, regulatory submissions, and financial projections. These statements involve risks and uncertainties, and actual results could differ materially from those projected. InvestingPro analysis shows the company maintains a strong liquidity position with a current ratio of 7.28, though it faces challenges with rapid cash burn and weak profit margins. Notably, analyst price targets range from $11 to $20, suggesting significant potential upside from current levels. Get deeper insights and access to 5 additional exclusive ProTips with an InvestingPro subscription.
The information presented here is based on a press release statement from Aprea Therapeutics. Based on InvestingPro’s Fair Value analysis, the stock appears to be currently undervalued, though investors should note that the company is not yet profitable and does not pay dividends. Discover comprehensive financial analysis and real-time alerts by visiting our Most Undervalued Stocks watchlist.
In other recent news, Aprea Therapeutics has been making significant strides in its clinical development programs. The biopharmaceutical company has been reaffirmed with a Buy rating by H.C. Wainwright, which also set a $20.00 price target on the stock. This decision was influenced by Aprea’s recent clinical pipeline update and its projected milestones for the upcoming year.
Aprea is currently advancing two precision oncology programs, APR-1051 and ATRN-119, targeting the treatment of solid tumors. The company expects to have approximately $22.8 million in cash by the end of 2024, sufficient to support ongoing operations for at least the next 12 months.
The firm is enrolling patients into the fourth cohort of the ACESOT-1051 Phase 1 clinical trial, with the first look at the open-label safety and efficacy data for APR-1051 expected by mid-2025. Simultaneously, the ATRN-119 program is progressing in the Phase 1/2a ABOYA-119 study, with the Phase 1 readout expected in the second half of 2025.
H.C. Wainwright’s continued confidence in Aprea’s strategic focus and execution is evident in their maintained Buy rating and price target. The company is also planning to announce a third candidate, another DDR (NYSE:SITC) inhibitor, which could potentially expand its oncology pipeline further. These recent developments highlight Aprea Therapeutics’ commitment to advancing cancer therapies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.